Fintel reports that BlackRock has filed a 13G/A form with the SEC disclosing ownership of 172.72MM shares of Bristol-Myers Squibb Co (BMY). This represents 8.1% of the company.
In their previous filing dated February 1, 2022 they reported 169.23MM shares and 7.60% of the company, an increase in shares of 2.06% and an increase in total ownership of 0.50% (calculated as current - previous percent ownership).
Analyst Price Forecast Suggests 11.63% Upside
As of February 6, 2023, the average one-year price target for Bristol-Myers Squibb is $83.20. The forecasts range from a low of $60.60 to a high of $96.60. The average price target represents an increase of 11.63% from its latest reported closing price of $74.53.
The projected annual revenue for Bristol-Myers Squibb is $47,586MM, an increase of 3.09%. The projected annual EPS is $8.03, an increase of 170.35%.
Fund Sentiment
There are 3842 funds or institutions reporting positions in Bristol-Myers Squibb. This is a decrease of 16 owner(s) or 0.41%.
Average portfolio weight of all funds dedicated to US:BMY is 0.6901%, a decrease of 1.3393%. Total shares owned by institutions increased in the last three months by 0.76% to 1,878,378K shares.
What are large shareholders doing?
Jpmorgan Chase & holds 99,498,153 shares representing 4.48% ownership of the company. In it's prior filing, the firm reported owning 97,760,260 shares, representing an increase of 1.75%. The firm decreased its portfolio allocation in BMY by 3.14% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 63,698,218 shares representing 2.87% ownership of the company. In it's prior filing, the firm reported owning 62,685,891 shares, representing an increase of 1.59%. The firm decreased its portfolio allocation in BMY by 2.21% over the last quarter.
Capital International Investors holds 52,396,432 shares representing 2.36% ownership of the company. In it's prior filing, the firm reported owning 38,097,912 shares, representing an increase of 27.29%. The firm increased its portfolio allocation in BMY by 36.16% over the last quarter.
VFINX - Vanguard 500 Index Fund Investor Shares holds 48,403,969 shares representing 2.18% ownership of the company. In it's prior filing, the firm reported owning 47,124,488 shares, representing an increase of 2.64%. The firm decreased its portfolio allocation in BMY by 1.94% over the last quarter.
Bank Of America holds 45,187,751 shares representing 2.04% ownership of the company. In it's prior filing, the firm reported owning 46,635,490 shares, representing a decrease of 3.20%. The firm decreased its portfolio allocation in BMY by 6.03% over the last quarter.
Bristol-Myers Squibb Declares $0.57 Dividend
Bristol-Myers Squibb said on December 8, 2022 that its board of directors declared a regular quarterly dividend of $0.57 per share ($2.28 annualized). Shareholders of record as of January 5, 2023 received the payment on February 1, 2023. Previously, the company paid $0.54 per share.
At the current share price of $74.53 / share, the stock's dividend yield is 3.06%. Looking back five years and taking a sample every week, the average dividend yield has been 3.06%, the lowest has been 2.33%, and the highest has been 3.88%. The standard deviation of yields is 0.27 (n=236).
The current dividend yield is 0.01 standard deviations above the historical average.
Additionally, the company's dividend payout ratio is 0.80. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.
The company's 3-Year dividend growth rate is 0.27%, demonstrating that it has increased its dividend over time.
Bristol-Myers Squibb Background Information
(This description is provided by the company.)
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
